Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Anti-cancer drug development is inefficient, mostly due to lack of efficacy in human patients.
The high fail rate is partly due to the lack of predictive models or the inadequate use of …

Chronic inflammation and an immunosuppressive microenvironment promote prostate
cancer (PCa) progression and diminish the response to immune checkpoint blockade (ICB) …

This protocol describes a strategy for the generation of 3D prostate organoid cultures from
healthy mouse and human prostate cells (either bulk or FACS-sorted single luminal and …

INTRODUCTION Inhibition of oncogenic proteins represents a mainstay approach for cancer
therapeutic development. By contrast, pharmacological modulation of tumor suppressor …

The level of SETD2-mediated H3K36me3 is inversely correlated with that of EZH2-catalyzed
H3K27me3. Nevertheless, it remains unclear whether these two enzymatic activities are …

Cytotoxic chemotherapy is effective in debulking tumour masses initially; however, in some
patients tumours become progressively unresponsive after multiple treatment cycles …

Lipids, either endogenously synthesized or exogenous, have been linked to human cancer.
Here we found that PML is frequently co-deleted with PTEN in metastatic human prostate …

The mammalian target of rapamycin (mTOR) kinase is a master regulator of protein
synthesis that couples nutrient sensing to cell growth and cancer. However, the downstream …

Lung squamous cell carcinoma (LSCC) pathogenesis remains incompletely understood,
and biomarkers predicting treatment response remain lacking. Here, we describe novel …